Published in Antimicrob Agents Chemother on September 01, 1992
Current perspectives on glycopeptide resistance. Clin Microbiol Rev (1995) 2.99
In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers. Antimicrob Agents Chemother (2001) 2.14
Thrombin-induced platelet microbicidal protein susceptibility phenotype influences the outcome of oxacillin prophylaxis and therapy of experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother (2000) 1.01
Enterococcal endocarditis: can we win the war? Curr Infect Dis Rep (2012) 0.88
Daptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococci. Int J Antimicrob Agents (2014) 0.87
Daptomycin: a novel lipopeptide antibiotic against Gram-positive pathogens. Infect Drug Resist (2010) 0.84
What's New in the Treatment of Enterococcal Endocarditis? Curr Infect Dis Rep (2014) 0.79
Activity of daptomycin or linezolid in combination with rifampin or gentamicin against biofilm-forming Enterococcus faecalis or E. faecium in an in vitro pharmacodynamic model using simulated endocardial vegetations and an in vivo survival assay using Galleria mellonella larvae. Antimicrob Agents Chemother (2014) 0.77
Pharmacodynamics of Ceftaroline Plus Ampicillin Against Enterococcus faecalis in an in vitro Pharmacokinetic/Pharmacodynamic Model of Simulated Endocardial Vegetations. Antimicrob Agents Chemother (2017) 0.75
Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med (1988) 16.74
Rapid dissemination of beta-lactamase-producing, aminoglycoside-resistant Enterococcus faecalis among patients and staff on an infant-toddler surgical ward. N Engl J Med (1990) 4.40
Antibiotic synergism in enterococcal endocarditis. J Lab Clin Med (1976) 3.79
Comparison of two beta-lactamase-producing strains of Streptococcus faecalis. Antimicrob Agents Chemother (1986) 3.33
High-level penicillin resistance among isolates of enterococci. Implications for treatment of enterococcal infections. Ann Intern Med (1989) 3.02
Enterococci highly resistant to penicillin and ampicillin: an emerging clinical problem? J Clin Microbiol (1989) 2.51
Daptomycin (LY146032) treatment of experimental enterococcal endocarditis. Antimicrob Agents Chemother (1988) 2.47
Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin (LY146032). Antimicrob Agents Chemother (1990) 2.40
In vitro studies of plasmid-mediated penicillinase from Streptococcus faecalis suggest a staphylococcal origin. J Clin Invest (1986) 2.31
beta-Lactamase production in experimental endocarditis due to aminoglycoside-resistant Streptococcus faecalis. J Infect Dis (1987) 2.17
Serious infection due to beta-lactamase-producing Streptococcus faecalis with high-level resistance to gentamicin. J Infect Dis (1988) 2.03
Ampicillin-resistant enterococcal species in an acute-care hospital. Antimicrob Agents Chemother (1990) 1.83
Infections due to beta-lactamase-producing, high-level gentamicin-resistant Enterococcus faecalis. Ann Intern Med (1992) 1.76
Chromosomally mediated beta-lactamase production and gentamicin resistance in Enterococcus faecalis. Antimicrob Agents Chemother (1991) 1.75
Treatment of experimental endocarditis caused by a beta-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin. Antimicrob Agents Chemother (1989) 1.47
Chemoprophylactic efficacy against experimental endocarditis caused by beta-lactamase-producing, aminoglycoside-resistant enterococci is associated with prolonged serum inhibitory activity. Antimicrob Agents Chemother (1990) 1.38
Comparison of Enterococcus raffinosus with Enterococcus avium on the basis of penicillin susceptibility, penicillin-binding protein analysis, and high-level aminoglycoside resistance. Antimicrob Agents Chemother (1991) 1.35
Different modes of vancomycin and D-alanyl-D-alanine peptidase binding to cell wall peptide and a possible role for the vancomycin resistance protein. Antimicrob Agents Chemother (1990) 1.15
LY146032 compared with penicillin G in experimental aortic valve endocarditis caused by group G streptococci. Antimicrob Agents Chemother (1988) 1.10
Changing pattern of infective endocarditis. Am J Med (1985) 1.10
Penicillin-induced effects on streptomycin uptake and early bactericidal activity differ in viridans group and enterococcal streptococci. Antimicrob Agents Chemother (1986) 1.00
In vitro activity and mechanism of action of A21978C1, a novel cyclic lipopeptide antibiotic. Antimicrob Agents Chemother (1985) 7.83
In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent. Antimicrob Agents Chemother (1984) 7.14
Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet (2001) 5.90
Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility. Antimicrob Agents Chemother (1990) 5.81
In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic. Antimicrob Agents Chemother (1986) 5.30
Evidence for clonal spread of a single strain of beta-lactamase-producing Enterococcus (Streptococcus) faecalis to six hospitals in five states. J Infect Dis (1991) 4.82
Diagnosis and management of infective endocarditis and its complications. Circulation (1999) 4.77
Rapid dissemination of beta-lactamase-producing, aminoglycoside-resistant Enterococcus faecalis among patients and staff on an infant-toddler surgical ward. N Engl J Med (1990) 4.40
Diminished virulence of a sar-/agr- mutant of Staphylococcus aureus in the rabbit model of endocarditis. J Clin Invest (1994) 4.39
In-vitro activity of Sch 29482 in comparison with other oral antibiotics. J Antimicrob Chemother (1982) 3.95
Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds. J Antimicrob Chemother (1988) 3.80
Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother (1999) 3.16
Staphylococcus aureus genetic loci impacting growth and survival in multiple infection environments. Mol Microbiol (1998) 3.04
Increasing resistance to beta-lactam antibiotics among clinical isolates of Enterococcus faecium: a 22-year review at one institution. Antimicrob Agents Chemother (1991) 3.00
Susceptibility of enterococci and Listeria monocytogenes to N-Formimidoyl thienamycin alone and in combination with an aminoglycoside. Antimicrob Agents Chemother (1981) 2.88
Mechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound. Antimicrob Agents Chemother (1988) 2.83
Resistance to beta-lactam antibiotics in Streptococcus faecium. Antimicrob Agents Chemother (1982) 2.68
Serious infections in adults due to group B streptococci. Clinical and serotypic characterization. Am J Med (1976) 2.58
Colonization with broad-spectrum cephalosporin-resistant gram-negative bacilli in intensive care units during a nonoutbreak period: prevalence, risk factors, and rate of infection. Crit Care Med (1999) 2.56
A gene conferring resistance to vancomycin but not teicoplanin in isolates of Enterococcus faecalis and Enterococcus faecium demonstrates homology with vanB, vanA, and vanC genes of enterococci. Antimicrob Agents Chemother (1993) 2.56
Partial characterization and staphylocidal activity of thrombin-induced platelet microbicidal protein. Infect Immun (1992) 2.53
Lactobacillemia--report of nine cases. Important clinical and therapeutic considerations. Am J Med (1978) 2.46
The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy. Clin Infect Dis (2008) 2.39
Continuous-infusion ampicillin therapy of enterococcal endocarditis in rats. Antimicrob Agents Chemother (1987) 2.35
Hyperproduction of alpha-hemolysin in a sigB mutant is associated with elevated SarA expression in Staphylococcus aureus. Infect Immun (1999) 2.35
Methicillin-resistant Staphylococcus aureus: comparison of susceptibility testing methods and analysis of mecA-positive susceptible strains. J Clin Microbiol (2001) 2.31
Platelet microbicidal proteins and neutrophil defensin disrupt the Staphylococcus aureus cytoplasmic membrane by distinct mechanisms of action. J Clin Invest (1998) 2.29
In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother (1993) 2.29
Effect of thrombocytopenia on the early course of streptococcal endocarditis. J Infect Dis (1993) 2.18
In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria. Antimicrob Agents Chemother (2000) 2.18
SME-type carbapenem-hydrolyzing class A beta-lactamases from geographically diverse Serratia marcescens strains. Antimicrob Agents Chemother (2000) 2.15
Pulmonary aspergilloma. Diagnostic and therapeutic considerations. Arch Intern Med (1983) 2.13
Acute interstitial nephritis due to methicillin. Am J Med (1978) 2.11
Transesophageal echocardiography in diagnosis of infective endocarditis. Chest (1994) 2.11
Characterization of mechanisms of quinolone resistance in Pseudomonas aeruginosa strains isolated in vitro and in vivo during experimental endocarditis. Antimicrob Agents Chemother (1989) 2.05
Circulating immune complexes in infective endocarditis. N Engl J Med (1976) 2.02
In vitro activities of the quinolone antimicrobial agents A-56619 and A-56620. Antimicrob Agents Chemother (1985) 1.99
Group D enterococcal meningitis. Clinical and therapeutic considerations with report of three cases and review of the literature. Arch Intern Med (1976) 1.98
Tuberculin-purified protein derivative-, MPT-64-, and ESAT-6-stimulated gamma interferon responses in medical students before and after Mycobacterium bovis BCG vaccination and in patients with tuberculosis. Clin Diagn Lab Immunol (1999) 1.97
In vitro activity of RU 64004, a new ketolide antibiotic, against gram-positive bacteria. Antimicrob Agents Chemother (1997) 1.96
Purification and in vitro activities of rabbit platelet microbicidal proteins. Infect Immun (1997) 1.96
Efficacy of different beta-lactams against an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain in the rat intra-abdominal abscess model. Antimicrob Agents Chemother (1991) 1.94
Resistance to penicillin-streptomycin synergy among clinical isolates of viridans streptococci. Antimicrob Agents Chemother (1983) 1.93
Malaria acquired in Bali. Med J Aust (1995) 1.93
Role of the sar locus of Staphylococcus aureus in induction of endocarditis in rabbits. Infect Immun (1994) 1.92
Direct detection of vanB2 using the Roche LightCycler vanA/B detection assay to indicate vancomycin-resistant enterococcal carriage--sensitive but not specific. J Antimicrob Chemother (2007) 1.88
Staphylococcus aureus susceptibility to thrombin-induced platelet microbicidal protein is independent of platelet adherence and aggregation in vitro. Infect Immun (1992) 1.84
Characterization of Staphylococcus aureus-platelet binding by quantitative flow cytometric analysis. J Infect Dis (1992) 1.84
In vitro resistance to platelet microbicidal protein correlates with endocarditis source among bacteremic staphylococcal and streptococcal isolates. Antimicrob Agents Chemother (1994) 1.83
Comparison of three PCR primer sets for identification of vanB gene carriage in feces and correlation with carriage of vancomycin-resistant enterococci: interference by vanB-containing anaerobic bacilli. Antimicrob Agents Chemother (2005) 1.81
Thrombin-induced rabbit platelet microbicidal protein is fungicidal in vitro. Antimicrob Agents Chemother (1993) 1.80
Staphylocidal action of thrombin-induced platelet microbicidal protein is not solely dependent on transmembrane potential. Infect Immun (1996) 1.79
Efficacy of vancomycin plus rifampin in experimental aortic-valve endocarditis due to methicillin-resistant Staphylococcus aureus: in vitro-in vivo correlations. J Infect Dis (1985) 1.78
In vitro antibacterial activities of platelet microbicidal protein and neutrophil defensin against Staphylococcus aureus are influenced by antibiotics differing in mechanism of action. Antimicrob Agents Chemother (1999) 1.77
Enterococcal endocarditis: a comparison of prosthetic and native valve disease. Rev Infect Dis (1991) 1.77
Chromosomally mediated beta-lactamase production and gentamicin resistance in Enterococcus faecalis. Antimicrob Agents Chemother (1991) 1.75
Multiply resistant viridans streptococci: susceptibility to beta-lactam antibiotics and comparison of penicillin-binding protein patterns. Antimicrob Agents Chemother (1983) 1.74
Selective activation of sar promoters with the use of green fluorescent protein transcriptional fusions as the detection system in the rabbit endocarditis model. Infect Immun (1998) 1.72
Beta-Lactam-beta-lactamase-inhibitor combinations are active in experimental endocarditis caused by beta-lactamase-producing oxacillin-resistant staphylococci. Antimicrob Agents Chemother (1991) 1.67
IgG rheumatoid factor in subacute bacterial endocarditis: relationship to IgM rheumatoid factor and circulating immune complexes. Clin Exp Immunol (1978) 1.62
Enterococcal vanB resistance locus in anaerobic bacteria in human faeces. Lancet (2001) 1.60
Is fosfomycin a potential treatment alternative for multidrug-resistant gram-negative prostatitis? Clin Infect Dis (2013) 1.60
Platelet microbicidal protein enhances antibiotic-induced killing of and postantibiotic effect in Staphylococcus aureus. Antimicrob Agents Chemother (1992) 1.59
Molecular characterization of vanB elements in naturally occurring gut anaerobes. Antimicrob Agents Chemother (2005) 1.58
Disparity between timed-kill and checkerboard methods for determination of in vitro bactericidal interactions of vancomycin plus rifampin versus methicillin-susceptible and -resistant Staphylococcus aureus. Antimicrob Agents Chemother (1984) 1.57
Serious infections due to group G streptoccocci. Report of 15 cases with in vitro-in vivo correlations. Am J Med (1983) 1.57
Necrotizing pneumonia and empyema due to Clostridium perfringens. Report of a case and review of the literature. Am J Med (1975) 1.56
In vitro activity of BMY-28100, a new oral cephalosporin. Antimicrob Agents Chemother (1987) 1.56
Azlocillin, mezlocillin, and piperacillin: new broad-spectrum penicillins. Ann Intern Med (1982) 1.55
Absence of synergistic activity between ampicillin and vancomycin against highly vancomycin-resistant enterococci. Antimicrob Agents Chemother (1992) 1.53
Systemic absorption of enteral vancomycin in a patient with pseudomembranous colitis. Ann Intern Med (1984) 1.52
Phenotypic resistance to thrombin-induced platelet microbicidal protein in vitro is correlated with enhanced virulence in experimental endocarditis due to Staphylococcus aureus. Infect Immun (1997) 1.51
Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA. Antimicrob Agents Chemother (2009) 1.50
Insertional inactivation of a chromosomal locus that modulates expression of potential virulence determinants in Staphylococcus aureus. J Bacteriol (1995) 1.47
Treatment of experimental endocarditis caused by a beta-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin. Antimicrob Agents Chemother (1989) 1.47
Ribosomal resistance of clinical enterococcal to streptomycin isolates. Antimicrob Agents Chemother (1984) 1.45
Diminished platelet binding in vitro by Staphylococcus aureus is associated with reduced virulence in a rabbit model of infective endocarditis. Infect Immun (1996) 1.45
Sepsis associated with decubitus ulcers. Am J Med (1976) 1.44
Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp. Antimicrob Agents Chemother (2001) 1.44
A comparison of two dosing regimens of zidovudine in Thai adults with early symptomatic HIV infection. Conducting clinical HIV trials in South-East Asia. Aust N Z J Med (2000) 1.42
Efficacy of amikacin and ceftazidime in experimental aortic valve endocarditis due to Pseudomonas aeruginosa. Antimicrob Agents Chemother (1985) 1.42
Efficacy of oxacillin and ampicillin-sulbactam combination in experimental endocarditis caused by beta-lactamase-hyperproducing Staphylococcus aureus. Antimicrob Agents Chemother (1990) 1.40
Increasing problems in the therapy of enterococcal infections. Eur J Clin Microbiol Infect Dis (1993) 1.39
Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum beta-lactamase-producing strain of Klebsiella pneumoniae. Antimicrob Agents Chemother (1997) 1.39
Clumping factor A mediates binding of Staphylococcus aureus to human platelets. Infect Immun (2001) 1.39
Resistance to platelet microbicidal protein results in increased severity of experimental Candida albicans endocarditis. Infect Immun (1996) 1.39
Preventing infection in neutropenic cancer patients. West J Med (1983) 1.38
HIV in the suburbs. Med J Aust (1993) 1.38
In vitro resistance to thrombin-induced platelet microbicidal protein is associated with enhanced progression and hematogenous dissemination in experimental Staphylococcus aureus infective endocarditis. Infect Immun (1998) 1.37
A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother (1996) 1.36
Antibiotic synergism and antimicrobial combinations in clinical infections. Rev Infect Dis (1982) 1.36
Influence of Staphylococcus aureus antibody on experimental endocarditis in rabbits. Infect Immun (1987) 1.35
Comparison of Enterococcus raffinosus with Enterococcus avium on the basis of penicillin susceptibility, penicillin-binding protein analysis, and high-level aminoglycoside resistance. Antimicrob Agents Chemother (1991) 1.35
In vitro inhibition of Helicobacter pylori NCTC 11637 by organic acids and lactic acid bacteria. J Appl Bacteriol (1995) 1.34
Analysis by gel electrophoresis, Western blot, and peptide mapping of protein A heterogeneity in Staphylococcus aureus strains. Infect Immun (1987) 1.33
In vitro activity of ramoplanin against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother (1993) 1.33
In vitro synergism between daptomycin and fosfomycin against Enterococcus faecalis isolates with high-level gentamicin resistance. Antimicrob Agents Chemother (1989) 1.33
Association between severe pandemic 2009 influenza A (H1N1) virus infection and immunoglobulin G(2) subclass deficiency. Clin Infect Dis (2010) 1.32
Identification and characterization of the PutP proline permease that contributes to in vivo survival of Staphylococcus aureus in animal models. Infect Immun (1998) 1.29